Organon & Co. (OGN)

Organon & Co.'s stock price has experienced several notable events in the past six months. The stock price declined by 21.02% between April 11, 2025, and April 10, 2026, and decreased by 10.90% over the past six months. In November 2025, Organon reported its third-quarter 2025 financial results, with revenue up 1% as-reported but down 1% excluding foreign currency impact. On February 12, 2026, Organon released its fourth-quarter and full-year 2025 earnings report, with sales decreasing by 5.3% year-over-year to $1.51 billion. On February 20, 2026, Organon announced that its Audit Committee had completed an independent review into the timing of past biosimilar purchases, which led to a surge in the stock price. On April 10, 2026, Organon's stock surged following reports that Sun Pharmaceutical Industries had submitted a $12 billion binding offer to acquire the company.

Organon & Co. faces modest revenue headwinds, with growth products working to offset softness in its respiratory portfolio. The respiratory segment can experience seasonal fluctuations in demand. Demand for certain women's health products can also be affected by external factors. While the company's diverse portfolio aims to mitigate overall seasonality, specific product categories can experience varying demand patterns throughout the year.

Organon & Co. is a global healthcare company specializing in health solutions through prescription therapies and medical devices, operating within the Healthcare sector and Drug Manufacturers - General industry. Its business is structured around Women's Health, Biosimilars, and Established Brands. The Women's Health portfolio includes contraception and fertility brands. The Biosimilars portfolio provides treatments for immunology and oncology. The Established Brands encompass a broad range of therapeutic areas including cardiovascular medicines, respiratory products, dermatology products, bone health treatments, and non-opioid pain management products.

Organon & Co. has a significant global presence, with its products available in over 140 countries and territories. The company has a direct footprint in 62 countries and maintains collaborations in more than 80 others. Its headquarters are located in Jersey City, New Jersey, USA. Organon generates a majority of its revenue from Europe and Canada, followed by the United States, and then the Asia Pacific and Japan regions. The company also operates six manufacturing sites across Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the United Kingdom.

In the past year, Organon's brand reputation has been influenced by both challenges and positive developments. The completion of an independent audit review in February 2026, which found no evidence of improper conduct related to biosimilar purchases, likely had a positive impact on the company's reputation for financial integrity. Organon has also received industry recognition, including being recognized as a "Best Place to Work for Disability Inclusion" and included in "America's Most JUST Companies, JUST 100 Index" by JUST Capital. Fortune recognized Organon in its "Change the World" list for its efforts in expanding global access to contraception, and the She Is Global Forum named it "Organization of the Year with the Power to Generate Change Towards Gender Equity."

Organon & Co. is widely held by public and institutional investors, with no single family or founder controlling the company. Institutional investors collectively own the majority of Organon's stock, often ranging from 85% to 90% of outstanding shares. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., State Street Corp, Aqr Capital Management Llc, Lsv Asset Management, Massachusetts Financial Services Co /ma/, Geode Capital Management, Llc, Private Management Group Inc, UBS Group AG, and Kahn Brothers Group Inc /de/. Insider ownership is modest, typically 1-2% or less. There has been significant insider buying activity in 2025 with no offsetting sells.